PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
France Targets Shein, Temu With Fast-Fashion Fees 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Shein Shares Slide 9% in Hong Kong IPO Debut 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
OpenAI Rejects Apple Trade Secret Theft Claims 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Add as a preferred source on Google
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
